PT1699468E - Composição farmacêutica compreendendo um complexo de zinco-hialuronato para o tratamento de esclerose multipla. - Google Patents

Composição farmacêutica compreendendo um complexo de zinco-hialuronato para o tratamento de esclerose multipla. Download PDF

Info

Publication number: PT1699468E
Authority: PT; Portugal
Prior art keywords: zinc; treatment; complex; multiple sclerosis; eae
Prior art date: 2003-11-20

Application number

PT04798745T

Other languages

English (en)

Portuguese (pt)

Inventor

Janos Illes

Gaborne Forrai

Gyoergy Tibor Balogh

Andras Boros

Akosne Szekely

Original Assignee

Richter Gedeon Vegyeszet

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-11-20

Filing date

2004-11-18

Publication date

2007-06-05

2004-11-18 Application filed by Richter Gedeon Vegyeszet filed Critical Richter Gedeon Vegyeszet

2007-06-05 Publication of PT1699468E publication Critical patent/PT1699468E/pt

Links

201000006417 multiple sclerosis Diseases 0.000 title claims abstract description 22
238000011282 treatment Methods 0.000 title claims abstract description 21
239000008194 pharmaceutical composition Substances 0.000 title abstract description 11
VJVOFLWZDWLHNR-MRCUWXFGSA-N icosan-9-yl (z)-docos-13-enoate Chemical compound CCCCCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCCCCC\C=C/CCCCCCCC VJVOFLWZDWLHNR-MRCUWXFGSA-N 0.000 title 1
229920002674 hyaluronan Polymers 0.000 claims abstract description 50
229940099552 hyaluronan Drugs 0.000 claims abstract description 47
KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 claims description 38
239000000243 solution Substances 0.000 claims description 19
239000003814 drug Substances 0.000 claims description 15
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 9
229910052725 zinc Inorganic materials 0.000 claims description 9
239000011701 zinc Substances 0.000 claims description 9
238000002347 injection Methods 0.000 claims description 4
239000007924 injection Substances 0.000 claims description 4
238000001802 infusion Methods 0.000 claims description 3
238000001990 intravenous administration Methods 0.000 claims description 3
238000007920 subcutaneous administration Methods 0.000 claims description 3
238000007918 intramuscular administration Methods 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims 1
239000000654 additive Substances 0.000 abstract description 9
238000002360 preparation method Methods 0.000 abstract description 5
230000001225 therapeutic effect Effects 0.000 abstract description 5
230000000996 additive effect Effects 0.000 abstract description 4
238000000034 method Methods 0.000 abstract description 3
230000008569 process Effects 0.000 abstract description 3
239000004480 active ingredient Substances 0.000 abstract description 2
239000003937 drug carrier Substances 0.000 abstract description 2
239000013543 active substance Substances 0.000 description 23
239000000203 mixture Substances 0.000 description 23
201000002491 encephalomyelitis Diseases 0.000 description 19
230000000694 effects Effects 0.000 description 17
201000010099 disease Diseases 0.000 description 14
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
230000005764 inhibitory process Effects 0.000 description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
239000007864 aqueous solution Substances 0.000 description 7
229940079593 drug Drugs 0.000 description 7
239000011780 sodium chloride Substances 0.000 description 7
239000003981 vehicle Substances 0.000 description 7
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
238000003556 assay Methods 0.000 description 6
241001465754 Metazoa Species 0.000 description 5
210000004027 cell Anatomy 0.000 description 5
210000003169 central nervous system Anatomy 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
238000011835 investigation Methods 0.000 description 5
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
108010072051 Glatiramer Acetate Proteins 0.000 description 4
241000699670 Mus sp. Species 0.000 description 4
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 4
239000003125 aqueous solvent Substances 0.000 description 4
238000011081 inoculation Methods 0.000 description 4
239000003921 oil Substances 0.000 description 4
235000019198 oils Nutrition 0.000 description 4
239000000725 suspension Substances 0.000 description 4
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 3
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
108010005716 Interferon beta-1a Proteins 0.000 description 3
102000002233 Myelin-Oligodendrocyte Glycoprotein Human genes 0.000 description 3
108010000123 Myelin-Oligodendrocyte Glycoprotein Proteins 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
239000012153 distilled water Substances 0.000 description 3
230000036541 health Effects 0.000 description 3
229960003160 hyaluronic acid Drugs 0.000 description 3
229910052739 hydrogen Inorganic materials 0.000 description 3
239000001257 hydrogen Substances 0.000 description 3
230000037189 immune system physiology Effects 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
230000003993 interaction Effects 0.000 description 3
239000007788 liquid Substances 0.000 description 3
229920002521 macromolecule Polymers 0.000 description 3
210000004400 mucous membrane Anatomy 0.000 description 3
239000003755 preservative agent Substances 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
239000011734 sodium Substances 0.000 description 3
229910052708 sodium Inorganic materials 0.000 description 3
159000000000 sodium salts Chemical class 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
239000003826 tablet Substances 0.000 description 3
238000012360 testing method Methods 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
-1 versican Proteins 0.000 description 3
WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
244000215068 Acacia senegal Species 0.000 description 2
208000016192 Demyelinating disease Diseases 0.000 description 2
206010012305 Demyelination Diseases 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
229920000084 Gum arabic Polymers 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
108090000467 Interferon-beta Proteins 0.000 description 2
102000003996 Interferon-beta Human genes 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
229920002385 Sodium hyaluronate Polymers 0.000 description 2
210000001744 T-lymphocyte Anatomy 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
239000000205 acacia gum Substances 0.000 description 2
235000010489 acacia gum Nutrition 0.000 description 2
FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
230000008859 change Effects 0.000 description 2
229940038717 copaxone Drugs 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
150000002016 disaccharides Chemical class 0.000 description 2
210000002744 extracellular matrix Anatomy 0.000 description 2
239000000499 gel Substances 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
229960003776 glatiramer acetate Drugs 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
239000007937 lozenge Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000000463 material Substances 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
230000000704 physical effect Effects 0.000 description 2
230000035790 physiological processes and functions Effects 0.000 description 2
239000006187 pill Substances 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
229940010747 sodium hyaluronate Drugs 0.000 description 2
YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 2
239000008247 solid mixture Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
210000001179 synovial fluid Anatomy 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
102100036601 Aggrecan core protein Human genes 0.000 description 1
108010067219 Aggrecans Proteins 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
235000003911 Arachis Nutrition 0.000 description 1
244000105624 Arachis hypogaea Species 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
208000019838 Blood disease Diseases 0.000 description 1
108700031361 Brachyury Proteins 0.000 description 1
108010085074 Brevican Proteins 0.000 description 1
102100032312 Brevican core protein Human genes 0.000 description 1
102100032912 CD44 antigen Human genes 0.000 description 1
206010008469 Chest discomfort Diseases 0.000 description 1
206010015150 Erythema Diseases 0.000 description 1
208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
102100027735 Hyaluronan mediated motility receptor Human genes 0.000 description 1
206010022004 Influenza like illness Diseases 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
108010005714 Interferon beta-1b Proteins 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
238000000585 Mann–Whitney U test Methods 0.000 description 1
102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
102000006386 Myelin Proteins Human genes 0.000 description 1
108010083674 Myelin Proteins Proteins 0.000 description 1
125000003047 N-acetyl group Chemical group 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
229930012538 Paclitaxel Natural products 0.000 description 1
206010033557 Palpitations Diseases 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
108010067787 Proteoglycans Proteins 0.000 description 1
102000016611 Proteoglycans Human genes 0.000 description 1
QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
206010040914 Skin reaction Diseases 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
208000007107 Stomach Ulcer Diseases 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
208000031737 Tissue Adhesions Diseases 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
244000078912 Trichosanthes cucumerina Species 0.000 description 1
235000008322 Trichosanthes cucumerina Nutrition 0.000 description 1
102100032807 Tumor necrosis factor-inducible gene 6 protein Human genes 0.000 description 1
101710169430 Tumor necrosis factor-inducible gene 6 protein Proteins 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
206010052428 Wound Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
JIAARYAFYJHUJI-UHFFFAOYSA-L Zinc chloride Inorganic materials [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000007824 aliphatic compounds Chemical class 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000010775 animal oil Substances 0.000 description 1
230000000845 anti-microbial effect Effects 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
239000008135 aqueous vehicle Substances 0.000 description 1
229940003504 avonex Drugs 0.000 description 1
210000003050 axon Anatomy 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
229960000686 benzalkonium chloride Drugs 0.000 description 1
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
230000037396 body weight Effects 0.000 description 1
229910021538 borax Inorganic materials 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
230000033077 cellular process Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
208000037976 chronic inflammation Diseases 0.000 description 1
230000006020 chronic inflammation Effects 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
229910017052 cobalt Inorganic materials 0.000 description 1
239000010941 cobalt Substances 0.000 description 1
GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
239000003086 colorant Substances 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
239000000824 cytostatic agent Substances 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
239000006196 drop Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
201000005917 gastric ulcer Diseases 0.000 description 1
230000002178 gastroprotective effect Effects 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
229960002442 glucosamine Drugs 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
208000024908 graft versus host disease Diseases 0.000 description 1
208000014951 hematologic disease Diseases 0.000 description 1
208000018706 hematopoietic system disease Diseases 0.000 description 1
229920001519 homopolymer Polymers 0.000 description 1
108010003425 hyaluronan-mediated motility receptor Proteins 0.000 description 1
239000000017 hydrogel Substances 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
229960004461 interferon beta-1a Drugs 0.000 description 1
229960003161 interferon beta-1b Drugs 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
230000003902 lesion Effects 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000003137 locomotive effect Effects 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
230000003340 mental effect Effects 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
150000002772 monosaccharides Chemical class 0.000 description 1
210000005012 myelin Anatomy 0.000 description 1
210000004165 myocardium Anatomy 0.000 description 1
210000002850 nasal mucosa Anatomy 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
230000004770 neurodegeneration Effects 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
210000004498 neuroglial cell Anatomy 0.000 description 1
239000002674 ointment Substances 0.000 description 1
210000004248 oligodendroglia Anatomy 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
229960001592 paclitaxel Drugs 0.000 description 1
102000045222 parkin Human genes 0.000 description 1
230000007170 pathology Effects 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
208000022821 personality disease Diseases 0.000 description 1
229940067107 phenylethyl alcohol Drugs 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
229960001416 pilocarpine Drugs 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
229940068984 polyvinyl alcohol Drugs 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
230000003334 potential effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
229940038850 rebif Drugs 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
230000029058 respiratory gaseous exchange Effects 0.000 description 1
238000000518 rheometry Methods 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
230000001953 sensory effect Effects 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
230000035483 skin reaction Effects 0.000 description 1
231100000430 skin reaction Toxicity 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
229910000342 sodium bisulfate Inorganic materials 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
235000017550 sodium carbonate Nutrition 0.000 description 1
235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
235000011008 sodium phosphates Nutrition 0.000 description 1
235000010339 sodium tetraborate Nutrition 0.000 description 1
AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
235000019345 sodium thiosulphate Nutrition 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
229940033663 thimerosal Drugs 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
108091005703 transmembrane proteins Proteins 0.000 description 1
102000035160 transmembrane proteins Human genes 0.000 description 1
BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
210000004127 vitreous body Anatomy 0.000 description 1
230000029663 wound healing Effects 0.000 description 1
150000003751 zinc Chemical class 0.000 description 1
235000005074 zinc chloride Nutrition 0.000 description 1
239000011592 zinc chloride Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Inorganic Chemistry (AREA)
Dermatology (AREA)
Molecular Biology (AREA)
Psychiatry (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

PT04798745T 2003-11-20 2004-11-18 Composição farmacêutica compreendendo um complexo de zinco-hialuronato para o tratamento de esclerose multipla. PT1699468E (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
HU0303779A HUP0303779A2 (en)	2003-11-20	2003-11-20	Pharmaceutical compositions containing hyaluronan complex for the treatment of sclerosis multiplex

Publications (1)

Publication Number	Publication Date
PT1699468E true PT1699468E (pt)	2007-06-05

Family

ID=90001707

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT04798745T PT1699468E (pt)	2003-11-20	2004-11-18	Composição farmacêutica compreendendo um complexo de zinco-hialuronato para o tratamento de esclerose multipla.

Country Status (20)

Country	Link
US (1)	US20070123488A1 (fr)
EP (1)	EP1699468B1 (fr)
JP (1)	JP4778908B2 (fr)
CN (1)	CN1882352B (fr)
AT (1)	ATE359800T1 (fr)
CY (1)	CY1106617T1 (fr)
DE (1)	DE602004006024T2 (fr)
DK (1)	DK1699468T3 (fr)
EA (1)	EA009209B1 (fr)
ES (1)	ES2286698T3 (fr)
HK (1)	HK1098352A1 (fr)
HR (1)	HRP20070291T3 (fr)
HU (1)	HUP0303779A2 (fr)
NO (1)	NO336121B1 (fr)
PL (1)	PL1699468T3 (fr)
PT (1)	PT1699468E (fr)
RS (2)	RS50523B (fr)
SI (1)	SI1699468T1 (fr)
UA (1)	UA83516C2 (fr)
WO (1)	WO2005049047A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20070099867A1 (en) *	2005-05-24	2007-05-03	Glycoscience Laboratories, Inc.	Pharmaceutical agent containing hyaluronan as an active ingredient
JP2007153761A (ja) *	2005-12-01	2007-06-21	Toshitsu Kagaku Kenkyusho:Kk	シナプス伝達促進剤及びシナプス保護剤
NO20064337L (no) *	2005-09-26	2007-03-27	Glycoscience Lab Inc	Farmasoytisk middel inneholdende hyaluronan som en aktiv ingrediens
JP2009091248A (ja) *	2006-01-17	2009-04-30	Toshitsu Kagaku Kenkyusho:Kk	外傷性神経障害および／または運動機能障害の治療薬
CN101389342B (zh)	2006-12-05	2012-08-08	株式会社糖质科学研究所	用于变性关节炎的治疗剂
JP2007277258A (ja) *	2007-06-20	2007-10-25	Toshitsu Kagaku Kenkyusho:Kk	炎症及び神経疾患の治療剤及び予防剤
LT2949335T (lt) *	2009-08-20	2017-03-27	Yeda Research & Development Company, Ltd.	Žemo dažnio glatiramero acetato terapija
CN111647100B (zh) *	2020-07-14	2022-03-01	山东华熙海御生物医药有限公司	一种高分子量透明质酸锌的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HU203372B (en) *	1989-02-24	1991-07-29	Richter Gedeon Vegyeszet	Process for producing hyaluronic associates and pharmaceutical compositions and cosmetics comprising such active ingredient
JP3419785B2 (ja) *	1995-09-28	2003-06-23	サングスタットメディカルコーポレイション	免疫抑制剤としてのヒアルロン酸の使用
HU225991B1 (en) *	1997-04-29	2008-02-28	Richter Gedeon Nyrt	Use of the zinc hyaluronate associate (complex) for the preparation of pharmaceutical compositions for oral use against peptic ulcer
DE19721099C2 (de) *	1997-05-20	1999-12-02	Fumapharm Ag Muri	Verwendung von Fumarsäurederivaten
JP2003089647A (ja) *	1999-03-10	2003-03-28	Takada Seiyaku Kk	関節性疾患治療剤
JP2001163789A (ja) *	1999-12-13	2001-06-19	Maruho Co Ltd	マトリックスメタロプロテアーゼ阻害用医薬組成物
BG104880A (en) *	2000-10-24	2002-04-30	Иван ХРИСТОВ	Medicamentous preparation for multiple sclerosis treatment
ATE417617T1 (de) *	2001-03-15	2009-01-15	Seikagaku Kogyo Co Ltd	Mittel zur steurung der expression von il-12

2003
- 2003-11-20 HU HU0303779A patent/HUP0303779A2/hu unknown
2004
- 2004-11-18 PT PT04798745T patent/PT1699468E/pt unknown
- 2004-11-18 US US10/579,256 patent/US20070123488A1/en not_active Abandoned
- 2004-11-18 EP EP04798745A patent/EP1699468B1/fr active Active
- 2004-11-18 SI SI200430325T patent/SI1699468T1/sl unknown
- 2004-11-18 RS RSP-2007/0270A patent/RS50523B/sr unknown
- 2004-11-18 JP JP2006540634A patent/JP4778908B2/ja not_active Expired - Fee Related
- 2004-11-18 CN CN200480034039XA patent/CN1882352B/zh not_active Expired - Fee Related
- 2004-11-18 WO PCT/HU2004/000107 patent/WO2005049047A1/fr active Application Filing
- 2004-11-18 PL PL04798745T patent/PL1699468T3/pl unknown
- 2004-11-18 UA UAA200606730A patent/UA83516C2/uk unknown
- 2004-11-18 DE DE602004006024T patent/DE602004006024T2/de active Active
- 2004-11-18 DK DK04798745T patent/DK1699468T3/da active
- 2004-11-18 ES ES04798745T patent/ES2286698T3/es active Active
- 2004-11-18 EA EA200600998A patent/EA009209B1/ru not_active IP Right Cessation
- 2004-11-18 RS YUP-2006/0325A patent/RS20060325A/sr unknown
- 2004-11-18 AT AT04798745T patent/ATE359800T1/de active
2006
- 2006-06-19 NO NO20062857A patent/NO336121B1/no not_active IP Right Cessation
2007
- 2007-05-04 HK HK07104747.1A patent/HK1098352A1/xx not_active IP Right Cessation
- 2007-05-23 CY CY20071100698T patent/CY1106617T1/el unknown
- 2007-07-03 HR HR20070291T patent/HRP20070291T3/xx unknown

Also Published As

Publication number	Publication date
WO2005049047A1 (fr)	2005-06-02
HK1098352A1 (en)	2007-07-20
ES2286698T3 (es)	2007-12-01
HRP20070291T3 (en)	2007-10-31
DK1699468T3 (da)	2007-09-03
NO336121B1 (no)	2015-05-18
DE602004006024T2 (de)	2007-12-27
JP2007512311A (ja)	2007-05-17
RS20060325A (en)	2008-08-07
HUP0303779D0 (en)	2004-03-01
DE602004006024D1 (de)	2007-05-31
NO20062857L (no)	2006-08-18
CN1882352B (zh)	2010-08-04
EA200600998A1 (ru)	2006-10-27
PL1699468T3 (pl)	2007-09-28
CY1106617T1 (el)	2012-01-25
HUP0303779A2 (en)	2006-02-28
SI1699468T1 (sl)	2007-08-31
EA009209B1 (ru)	2007-12-28
JP4778908B2 (ja)	2011-09-21
EP1699468B1 (fr)	2007-04-18
US20070123488A1 (en)	2007-05-31
ATE359800T1 (de)	2007-05-15
RS50523B (sr)	2010-05-07
UA83516C2 (uk)	2008-07-25
CN1882352A (zh)	2006-12-20
EP1699468A1 (fr)	2006-09-13

Publication	Publication Date	Title
HU220758B1 (hu)	2002-05-28	Eljárás hialuronsavat és nem szteroid gyulladásgátlót tartalmazó, rák kezelésére alkalmas gyógyászati készítmények előállítására
NZ299281A (en)	2000-12-22	Use of hyaluronic acid in topical medicaments
KR100969634B1 (ko)	2010-07-14	글루코사민 또는 글루코사민 유도체를 포함하는 아토피성피부염 치료용 조성물 및 이를 사용하여 아토피성 피부염을치료하는 방법
EP1369119B1 (fr)	2008-12-17	Agents de regulation d'expression d'il-12
NO336121B1 (no)	2015-05-18	Farmasøytisk preparat omfattende et sink-hyaluronatkompleks for behandlingen av multippel sklerose og anvendelse av komplekset for fremstilling av et medikament.
ES2475790T3 (es)	2014-07-11	Composición oft�lmica basada en ácido lactobi�nico útil para reducir el edema de córnea e inflamación
EP0821963B1 (fr)	2001-11-28	Substance anticancereuse inhibant le processus metastatique cancereux
US6720011B1 (en)	2004-04-13	Injectable composition for cancer treatment
AU2004224510A1 (en)	2004-10-07	Remedy for nerve damage
EP0140998A1 (fr)	1985-05-15	Préparations ophtalmiques
US20070032451A1 (en)	2007-02-08	Blood soluble drag reducing hyaluronic acid
EP1444983B1 (fr)	2015-09-16	Agents permettant le traitement des affections abdominales inflammatoires
WO2008014686A1 (fr)	2008-02-07	Formulation contenant de l'héparine de faible masse moléculaire à des fins d'injection intraarticulaire
GB2422781A (en)	2006-08-09	Treatment of inflammatory disorders
CN116077512A (zh)	2023-05-09	曼那斯汀减轻化疗药物顺铂导致的多器官损伤的应用
US20170106011A1 (en)	2017-04-20	Methods of treating traumatic brain injury and sequelae
CN106507666A (zh)	2017-03-15	1，3‑丙二磺酸或其药学上可接受的盐用于治疗肉状瘤病的用途
WO2020107820A1 (fr)	2020-06-04	Préparation d'injection de cavité articulaire et utilisation associée
RU2554776C1 (ru)	2015-06-27	Средство для коррекции нарушений в легочной ткани при цитостатическом воздействии
RU2739746C9 (ru)	2021-02-15	Фармацевтическое средство для лечения артрологических заболеваний
AU2016308446A1 (en)	2018-04-12	Polymers and their methods of use
CA2259773A1 (fr)	1999-07-22	Agent antifibrosique
WO2017088177A1 (fr)	2017-06-01	Produit à base de protéines adhésives de moule, et utilisation de ce dernier pour prévenir et inhiber l'inflammation neuronale
JP4587637B2 (ja)	2010-11-24	神経ペプチドの産生・放出抑制剤
RU2166944C2 (ru)	2001-05-20	Плазмозамещающий раствор с гемокоррегирующими и иммуномодулирующими свойствами